Working… Menu

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01421524
Recruitment Status : Active, not recruiting
First Posted : August 23, 2011
Last Update Posted : January 20, 2021
Information provided by (Responsible Party):

Brief Summary:
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-stage clinical trials.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Lymphoma, Large B-Cell, Diffuse Pleiotropic Pathway Modifier Glioblastoma Lymphoma Primary Central Nervous System Lymphoma Drug: CC-122 Phase 1

Detailed Description:
This trial is enrolling additional Multiple Myeloma (MM) subjects in a separate cohort defined as MM-2 to evaluate tolerability, safety and preliminary efficacy of CC-122 formulated capsule alone or in combination with DEX on intermittent dosing schedule (5 of 7 days of the week) in Pomalidomide-naïve subjects. Preliminary efficacy data in Multiple Myeloma subjects, warrants further exploration of CC-122 in MM on intermittent schedules to assess if dose intensity and tolerability can be improved. Initially, patients will be treated with oral CC-122 for one month. During this time, various tests (involving blood and urine collections, ECGs, etc) will be performed. Those whose tumors stabilize or regress may continue receiving treatment for as long as they benefit from CC-122. Different dose levels of CC-122 will be tested in a dose-rising study design.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 271 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma.
Actual Study Start Date : September 12, 2011
Estimated Primary Completion Date : August 1, 2021
Estimated Study Completion Date : August 1, 2021

Arm Intervention/treatment
Experimental: CC-122 MM-2
A new MM cohort (MM-2) will be enrolled in order to evaluate tolerability, safety and preliminary efficacy of the CC-122 formulated capsule given on an intermittent schedule (5/7 days per week) in 2 parallel dose escalation cohorts (MM-2a and MM-2b, respectively) (DEX) in Pomalidomide naïve subjects
Drug: CC-122
CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are > 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).

Experimental: CC-122- DLBCL-2
A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week [5/7 days] and/or 21 continuous days out of 28 days per cycle [21/28 days]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
Drug: CC-122
One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.

Experimental: CC-122- GBM-2
A new GBM cohort (GBM-2) in order to evaluate doses of CC-122 above the 3 mg QD MTD determined in all comers in Part A. CC-122 dose will increase in 1 mg increments starting with 4 mg daily on a continuous schedule using the 3+3 design described in Part A in order to establish an MTD specific for GBM subjects. Following dose escalation, the cohort will be expanded at or below the new MTD in up to 20 total subjects.
Drug: CC-122
Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .

Experimental: Primary Central Nervous System Lymphoma (PCNSL)
During dose expansion of selected intermittent schedules, an additional cohort of up to 10 subjects with PCNSL will also be explored at the same dose and schedule as DLBCL to confirm some safety and preliminary efficacy signal
Drug: CC-122
Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.

Primary Outcome Measures :
  1. Dose-Limiting Toxicity (DLT) [ Time Frame: Up to approximately Day 28 ]

    Dose-limiting toxicities (DLTs) will be evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE):

    • A clinically relevant AE that is suspected to be related to CC-122 and starts ≤ 30 days of first dose (Cycle 1) and ≥ grade (Gr) 3 except for Alopecia, Gr3 rash of the acneiform or maculopapular type < 4 daysduration , Gr 3 diarrhea or vomiting lasting< 72 hours
    • Clinically relevant laboratory abnormality suspected to be related to CC-122 and that commences within 30 days of first dose and ≥ Gr3.
    • Hematological toxicities as follows: Any febrile neutropenia (NP), Gr4 NP > 7 days, Gr 4 thrombocytopenia > 24 hours, Any Gr 3/4 thrombocytopenia with clinically significant bleeding.
    • Gr 4 liver function tests (LFTs) or Gr 3 ALT with ≥ Gr2 bilirubin
    • Any AE suspected to be CC-122 related and necessitating dose reduction during Cycle 1.

  2. Pharmacokinetics- Cmax [ Time Frame: Up to day 22 ]
    Maximum observed concentration in plasma (Cmax)

  3. Pharmacokinetics- AUC [ Time Frame: Up to day 22 ]
    Area under the concentration-time curve

  4. Pharmacokinetics- tmax [ Time Frame: Up to day 22 ]
    Time to maximum concentration

  5. Pharmacokinetics- t1/2 [ Time Frame: Up to day 22 ]
    Terminal half-life

  6. Pharmacokinetics- CL/F [ Time Frame: Up to day 22 ]
    Apparent total body clearance

  7. Pharmacokinetics- Vz/F [ Time Frame: Up to day 22 ]
    Apparent volume of distribution

  8. Non-tolerated dose (NTD) [ Time Frame: Up to day 28 ]
    Is defined as the dose level at which ≥2 out of 6 evaluable subjects in any dose cohort with DLT.

  9. Maximum Tolerated Dose (MTD) [ Time Frame: Up to day 28 ]
    Is defined as the last dose level below the NTD with ≤1 out of 6 evaluable subjects with DLT) during Cycle (C) 1.

Secondary Outcome Measures :
  1. Response Rate [ Time Frame: up to approximately 6 months ]
    The response rate of each tumor types based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1), International Workshop Criteria (IWC) for Non-Hodgkin's Lymphoma (NHL), International Uniform Response Criteria for Multiple Myeloma (IURC), or Responses Assessment for Neuro-Oncology (RANO) working group for Glioblastama multiforme (GBM)

  2. Tissue concentration of CC-122 [ Time Frame: up to approximately 6 months ]
    Tissue concentration of CC-122 in salvage resection specimens from subjects with GBM (CNS primary tumor) or in cerebrospinal fluid (CSF) from subjects undergoing lumbar puncture.

  3. 6-month progression free survival (PFS) rate for GBM chort [ Time Frame: Up to approximately 6 months ]
    The primary efficacy variable for GBM chohort is 6-month progression free survival (PFS).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
  2. Men and women, 18 years or older, with histologically or cytologically-confirmed, advanced solid tumors, Non-Hodgkin Lymphona (NHL), Multiple Myloma (MM), or advanced unresectable solid tumors limited to the tumor types below.

    1. Subjects who have progressed on (or not been able to tolerate) standard anticancer therapy or for whom no standard anticancer therapy exists. Must have disease that is objectively measurable
    2. Measurable disease criteria:

      • Subjects with Glioblastoma multiforme (GBM) do not have to have objectively measurable disease at entry.
      • For MM, Diffuse large B-cell lymphoma (DLBCL): Subjects must have disease that is objectively measurable, measurable levels of myeloma paraprotein in serum (> 0.5 g/dL) or urine (> 0.2 g excreted in a 24-hour collection sample) for MM and measurable disease by Internatonal Working Group (IWG) for NHL (with at least one measurable lesion's longest diameter ≥ 2cm).
      • For Primary Central Nervous System (CNS) Lymphoma (PCNSL): Subjects must have disease that is objectively measurable by International Workshop to Standardize Baseline Evaluation and Response Criteria in Primary CNS Lymphoma, Cerebrospinal Fluid (CSF) cytology (in case of leptomeningeal only disease), or vitreal aspiration cytology and/or retinal photographs (in case of ocular lymphoma).
  3. Tumor specific inclusion criteria:

    • DLBCL-2 cohort:

      • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
      • Histologically proven diffuse large B-cell non-Hodgkin's lymphoma
      • Must have progressed following or have been unable to tolerate at least one prior anthracycline or alkylating agent containing regimen (with or without anti-CD20).
      • Platelets ≥ 60 x 109/L.
    • For PCNSL cohort:

      • ECOG Performance Status of ≤ 2
      • Recurrent/refractory CNS non-Hodgkin's lymphoma involving CNS (Brain, Cerebrospinal fluid (CSF) or intraocular compartments)
      • Stable dose of glucocorticoids pre-therapy. If patients are receiving glucocorticoids, the dose should not increase during the 96 hours prior to initiation of therapy.
      • ECOG Performance Status of ≤ 2.
    • For glioblastoma multiforme (GBM-2) cohort:

      • ECOG Performance Status of ≤ 2
      • Primary GBM or gliosarcoma
      • ECOG Performance Status of ≤ 2.
      • Has received prior treatment including radiation and chemotherapy, with radiation completed > 12 weeks prior to Day 1 (or ≥ 4 weeks if the recurrence is outside of the prior radiation field).
      • Progression of disease after last therapy demonstrated by RANO criteria
      • No prior therapy with Avastin
      • No prior or scheduled Gliadel® wafer implant unless area of assessment and planned resection is outside the region previously implanted.
      • No prior interstitial brachytherapy or stereotactic radiosurgery unless area of assessment and planned resection is outside the region previously treated.
      • No enzyme-inducing anti-epileptic drugs (EIAED) such as carbamazepine, phenytoin, phenobarbital, or primidone within 14 days before Day 1.
      • Able to undergo repeated magnetic resonance imaging (magnetic resonance imaging (MRI), computed tomography (CT) scans).
      • Availability of adequate Formalin-fixed, paraffin embedded (FFPE) archival tumor material.
      • Platelets (plt) ≥ 100 x 109/L.
    • For Multiple Myeloma cohort

      • ECOG Performance Status of ≤ 1.
      • Have a documented diagnosis of multiple myeloma and have relapsed and refractory disease.
    • Measurable levels of myeloma paraprotein (M-protein) in serum (> 0.5 g/dL) or urine (> 0.2 g excreted in a 24-hour collection sample).

      • Patients must have received at least 2 prior therapies.
      • Patients must have relapsed after having achieved at least stable disease for at least one cycle of treatment to at least one prior regimen and then developed PD.
      • Patients must also have documented evidence of PD during or within 60 days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry (refractory disease).
      • Patients must have also undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of a proteosome inhibitor (either in separate regimens or within the same regimen).
      • Must be Pomalidomide naïve.
    • Last dose of therapeutic glucocorticosteroids given greater than 14 days prior to start of study treatment.
    • Platelets (plt) ≥ 75 x 109/L in subjects in whom < 50% of bone marrow mononuclear cells are plasma cells or ≥ 30 x 109/L in subjects in whom ≥ 50% of bone marrow mononuclear cells are plasma cells.
  4. At least 4 weeks from last dose of therapeutic glucocorticosteroids. Adrenal replacement doses of glucocorticosteroids (up to the equivalent of 10 mg daily prednisone) are allowed.
  5. Biopsies (DLBLC, MM): Diagnostic archival FFPE (either in tumor blocks or sectioned/mounted specimens) may be submitted in lieu of a pre-study research biopsy if it has been obtained no more than 1 year prior to enrollment and only after discussion with the Celgene Medical Monitor
  6. If not specified above as tumor specific parameter subjects must have the following laboratory and hematologic parameters as follows:

    1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if received pegfilgrastim).
    2. Hemoglobin (Hgb) ≥ 9 g/dL.
    3. Platelets (Plt) ≥100 x 109/L.
    4. Potassium within normal limits or correctable with supplements.
    5. AST/SGOT and ALT/SGPT ≤ 3 x upper limit of normal (ULN) or ≤ 5.0 x ULN if liver tumor is present.
    6. Serum creatinine ≤ ULN (with value applied to Cockcroft-Gault equation) or 24 hour clearance ≥ 50mL/min.
    7. Negative serum pregnancy test in females of childbearing potential

Exclusion Criteria:

  1. History of other carcinomas within the last 5 years except cured non-melanoma skin cancer, curatively treated in-situ cervical cancer, or localized prostate cancer with a current Prostate-specific antigen (PSA) of <1.0 mg/dL on 2 evaluations at least 3 months apart; the most recent evaluation must be no more than 4 weeks prior to Day 1 of the study drug, or other malignancies that were completely resected or treated Stage 1/2 lesions currently in complete remission.
  2. Symptomatic central nervous system metastases (excluding Glioblastoma multiforrme (GBM) and Primary Central Nervous System Lymphoma (PCNSL). Subjects with brain metastases that have been previously treated and are stable for 6 weeks are allowed.
  3. Known symptomatic acute or chronic pancreatitis.
  4. Any peripheral neuropathy ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade 2.
  5. Persistent diarrhea or malabsorption ≥ NCI CTCAE grade 2, despite medical management.
  6. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

    1. left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiography (ECHO).
    2. Complete left bundle branch, or bifasicular block.
    3. Congenital long QT syndrome.
    4. Persistent or uncontrolled ventricular arrhythmias or atrial fibrillation.
    5. QTcF > 460 msec on screening Electrocardiography (ECG) (mean of triplicate recordings).
    6. Unstable angina pectoris or myocardial infarction ≤ 3 months prior to starting CC-122.
    7. Troponin-T value > 0.4 ng/ml or BNP >300 pg/mL.

      ° Subjects with baseline troponin-T >Upper Limit of Normal (ULN) or B-type Natriuretic Peptide (BNP) >100 pg/mL are eligible but must have cardiologist evaluation prior to enrollment in the trial for baseline assessment and optimization of cardioprotective therapy.

    8. Other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension (blood pressure ≥ 160/95 mmHg).
  7. Other concurrent severe and/or uncontrolled concomitant medical conditions (eg, active or uncontrolled infection or renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol.
  8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks, whichever is shorter, prior to starting study drug or who have not recovered from side effects of such therapy.
  9. Major surgery ≤ 2 weeks prior to starting study drug or still recovering from post operative side effects.
  10. Women who are pregnant or breast feeding. Adults of reproductive potential not employing two forms of birth control as per Pregnancy Prevention Risk Management Plan.
  11. Known Human immunodeficiency virus (HIV) infection.
  12. Known chronic hepatitis B or C virus (HBV/HCV) infection, unless comorbidity in subjects with Hepatocellular carcinoma (HCC).
  13. Status post solid organ transplant.
  14. Less than 100 days for subjects receiving autologous hematologic stem cell transplant (HSCT); or 6 months for subjects receiving allogenic HSCT or either transplant type, if otherwise not fully recovered from HSCT related toxicity.
  15. For MM-2 cohort only: Hypersensitivity (eg, Rash Grade 3 or 4) to thalidomide, lenalidomide, or dexamethasone (MM-2b).
  16. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  17. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  18. Any condition that confounds the ability to interpret data from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01421524

Hide Hide 38 study locations
Layout table for location information
United States, California
City of Hope Cancer Center
Duarte, California, United States, 91010-300
UCLA Neuro-Oncology Program
Los Angeles, California, United States, 90095
University of California, San Francisco
San Francisco, California, United States, 9411
United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109
Henry Ford Medical Center - New Center One
Detroit, Michigan, United States, 48202-268
United States, Nevada
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States, 89169
United States, New Jersey
Rutgers Cancer Institute of New Jersey University
New Brunswick, New Jersey, United States, 08901
United States, New York
Mount Sinai Hospital
New York, New York, United States, 10029
Weill Medical College of Cornell University
New York, New York, United States, 10065
United States, South Carolina
MUSC Rheumatology and Immunology Dept.
Charleston, South Carolina, United States, 29425
Greenville Hospital System
Greenville, South Carolina, United States, 29605
United States, Tennessee
Sarah Cannon Research Institute Drug Development Unit
Nashville, Tennessee, United States, 37203
United States, Texas
Texas Oncology, PA - Dallas 75246
Dallas, Texas, United States, 75246
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States, 78229
United States, Washington
Swedish Medical Center Cancer Institute Research
Seattle, Washington, United States, 98104
Yakima Valley Memorial Hospital/ North Star Lodge
Yakima, Washington, United States, 98902
Cliniques Universitaires Saint-Luc
Bruxelles, Belgium, 1200
UZ Leuven
Leuven, Belgium, 3000
CU CHU Clemenceau
Caen Cedex, France, 14033
Paoli CalmettesHematology
Marseille le Cedex, France, 13273
Centre Hospitalier Lyon Sud
Pierre Bénite, France, 69495
Institut universitaire du cancer de Toulouse (IUCT) - Oncopole
Toulouse CEDEX 9, France, 31059
Institut Gustave Roussy
Villejuif Cedex, France, 94805
A.O.U. di Bologna Policlinico S.Orsola-Malpighi
Bologna, Italy, 40138
U.O.C. Ospedale Bellaria
Bologna, Italy, 40139
Istituto Nazionale Tumori
Milan, Italy
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale
Napoli, Campania, Italy, 80131
Istituto Nazionale Tumori Regina Elena, Struttura Complessa Ematologia ed Unita di Cellule Staminali
Roma, Italy, 00144
Istituto Clinico Humanitas
Rozzano (MI), Italy, 20089
Hospital Universitari Germans Trias i Pujol
Badalona (Barcelona), Spain, 8916
Hospital del Mar
Barcelona, Spain, 08003
Vall d´Hebron University Hospital
Barcelona, Spain, 08035
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain, 28040
Hospital 12 de Octubre
Madrid, Spain, 28041
Clinica Universidad de Navarra
Pamplona, Spain, 31008
Hospital Universitario de Salamanca
Salamanca, Spain, 37007
Hospital Virgen del Rocio
Sevilla, Spain, 41013
Hospital Universitario Clinico de Valencia
Valencia, Spain, 46010
Sponsors and Collaborators
Layout table for investigator information
Study Director: Michael Pourdehnad, MD Celgene Corporation
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Celgene Identifier: NCT01421524    
Other Study ID Numbers: CC-122-ST-001
U1111-1203-5132 ( Registry Identifier: WHO )
First Posted: August 23, 2011    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021
Keywords provided by Celgene:
Multiple Myeloma
DNA-PK inhibitor
Advanced Solid Tumors
Glioblastoma multiforme
Hepatocellular Carcinoma
Diffuse large B-cell lymphoma
Mantel Cell Lymphoma
Advanced unresectable Solid Tumors
Primary CNS Lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Lymphoma, Non-Hodgkin
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Lymphoma, B-Cell